A closer look at Hone Health’s 1,220-patient testosterone analysis, reported symptom changes and the evidence gaps around strength and body composition.
On September 25, 2026, Hone Health published an analysis of 1,220 women in perimenopause or menopause with testosterone prescriptions recorded through its service. The report compared patients’ questionnaire responses and described improvements in several menopause-related symptoms.
The clinical starting point is narrower than the idea of testosterone as a treatment for everything that changes at menopause. In its September 22, 2026 coverage of an FDA workshop, Medscape reported that experts viewed the evidence as strongest for hypoactive sexual desire disorder, or HSDD. They said benefits involving energy and muscle needed further study. The same applied to mood and cognition.
That distinction matters because a treatment goal should match the evidence supporting it. Distressing low sexual desire is a specific clinical concern. Feeling less energetic or wanting greater strength raises a different set of questions.
Sexual wellbeing deserves careful attention in its own right. It does not need to be presented as a route to more muscle or a different body shape to count as a legitimate health concern. Refemina’s discussion of the evidence behind testosterone for sexual difficulties provides related context.
Hone’s report brings patient experiences into this discussion. Its contribution is a description of reported symptom changes, rather than a replacement for the clinical evidence described by workshop experts.
Hone Health examined questionnaire responses among patients who met its inclusion criteria. The method and reported findings were:
These findings deserve attention because they concern experiences that matter in everyday life. Energy and physical capability are not minor concerns simply because they are reported through a questionnaire. The task is to understand precisely what that questionnaire assessed.
These words can sit together in a headline while describing different goals. A clinical conversation might focus on feeling more energetic during ordinary activities. Another might focus on physical strength or the stamina to remain active for longer.
Body composition is a separate goal again. Wanting a change in muscle tissue is not the same question as wanting daily life to feel less tiring. It is useful to keep those aims distinct when discussing any proposed treatment.
For this report, the most accurate description stays close to Hone’s wording: patients reported improvements in symptoms involving energy, strength and stamina. That gives their experiences a clear place in the discussion without turning the terms into interchangeable outcomes.
This distinction also protects the reader from a misleading shortcut. A broad phrase such as “better physical health” would blur the specific findings that Hone reported. Naming the outcome makes the conversation more precise and keeps the evidence attached to the question it actually addressed.
The FDA held a public workshop on testosterone use in menopausal women on September 17, 2026. Contemporary OB/GYN’s coverage described the meeting as taking place amid growing off-label use and continuing evidence gaps.
The workshop addressed questions about sexual function and cognition. It also included mood and musculoskeletal health. That breadth shows why testosterone discussions now extend beyond a single symptom, but a topic appearing on a workshop agenda is not the same as an established treatment benefit.
Medscape’s subsequent coverage retained the distinction between the strongest evidence for HSDD and the areas requiring further study. Hone’s patient report fits into that wider conversation as information about reported experiences.
The useful editorial reading is not that every proposed benefit now has equal support. It is that patient priorities and clinical research questions are both broadening. Each proposed use still needs to be judged against evidence relevant to that particular goal.
The limitations belong together because they define how far the analysis can be taken.
The design cannot establish a treatment effect. Hone’s analysis was observational and had no randomized control group. Comparing questionnaire responses over time identifies reported changes among these patients, but it cannot isolate testosterone from other influences or show that testosterone caused the changes.
The report did not quantify individual symptom improvements. Hone described the direction of change and which improvements were largest. It did not provide numerical or percentage changes for each symptom. The report therefore does not supply an effect size for a particular complaint.
Physical changes were not objectively measured in the reported analysis. It did not provide measurements showing gains in muscle mass or strength. Nor did it report objective changes in weight or body composition. A symptom involving strength should not be relabelled as a measured increase in physical performance.
The sample reflects a selected group within Hone’s service. Patients needed recorded prescriptions and repeated questionnaires to qualify. Hone also notes that its prescription records may omit hormone treatment received from other providers. The absence of another hormone prescription in those records does not establish that a patient received no such treatment elsewhere.
Long-term safety remains a wider evidence question. The FDA workshop addressed this among the knowledge gaps surrounding testosterone use in menopausal women.
Taken together, these boundaries make the analysis a signal about patient experiences. They do not make it a prediction of what an individual woman will gain from treatment.
The practical next step is a discussion with a qualified clinician about a clearly defined concern. That discussion can take patient reports seriously while keeping the proposed treatment goal connected to the relevant evidence.
The research supports questions such as:
For changes in energy, strength or body composition, the research supports a broader conversation rather than assuming that one hormone explains the whole picture. The goal is to understand the concern before attaching it to a particular prescription.
Refemina’s coverage of testosterone claims about midlife muscle offers another starting point for keeping that discussion focused on the evidence relevant to physical capability.
A useful conversation begins with language that describes the outcome being sought. “Feeling better” may be personally meaningful, but it leaves several different questions bundled together. Naming energy or strength separately gives the discussion a clearer direction.
The same applies when sexual desire is the central concern. That deserves its own assessment rather than being folded into a general body-composition conversation. Different goals should not borrow credibility from one another simply because the same hormone is being discussed.
The practical value of Hone’s analysis is that it identifies experiences worth asking about. It invites attention to how patients describe their lives and symptoms. The next step is matching those priorities with appropriate clinical assessment and evidence, not treating a patient report as a ready-made treatment plan.
Hone’s analysis should sharpen conversations about patients’ goals and guide further research, while clinical decisions remain anchored to evidence for the specific outcome being sought.
After reading testosterone patient reports, the next step is placing questions about strength and body composition within a fuller view of midlife health, the focus of Refemina’s research-led coverage. Refemina addresses uncertainty about changes in muscle, metabolism and weight through clear explanations that help readers separate credible evidence from broad hormonal claims and understand what remains unresolved.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources